These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27384680)

  • 1. Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells.
    Zovko A; Novak M; Hååg P; Kovalerchick D; Holmlund T; Färnegårdh K; Ilan M; Carmeli S; Lewensohn R; Viktorsson K
    Oncotarget; 2016 Aug; 7(31):50258-50276. PubMed ID: 27384680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
    Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.
    Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson HS; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
    Growth Factors; 2007 Feb; 25(1):1-8. PubMed ID: 17454144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma.
    Zovko A; Viktorsson K; Hååg P; Kovalerchick D; Färnegårdh K; Alimonti A; Ilan M; Carmeli S; Lewensohn R
    Mol Cancer Ther; 2014 Dec; 13(12):2941-54. PubMed ID: 25319389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
    Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
    Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 7. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
    Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
    Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
    Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
    Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-type-specific roles of IGF-1R and EGFR in mediating Zn2+-induced ERK1/2 and PKB phosphorylation.
    Pandey NR; Vardatsikos G; Mehdi MZ; Srivastava AK
    J Biol Inorg Chem; 2010 Mar; 15(3):399-407. PubMed ID: 19946718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer.
    Wei YH; Tang HX; Liao YD; Fu SL; Xu LQ; Chen G; Zhang C; Ju S; Liu ZG; You LK; Yu L; Zhou S
    J Huazhong Univ Sci Technolog Med Sci; 2015 Dec; 35(6):834-841. PubMed ID: 26670433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
    Lundholm L; Hååg P; Juntti T; Lewensohn R; Viktorsson K
    Int J Radiat Biol; 2014 Aug; 90(8):718-26. PubMed ID: 24646078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells.
    Bostedt KT; Schmid C; Ghirlanda-Keller C; Olie R; Winterhalter KH; Zapf J
    Exp Cell Res; 2001 Dec; 271(2):368-77. PubMed ID: 11716549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.